Mode
Text Size
Log in / Sign up
N/A N=40 Randomized Double-blind Basic Science

Insular Inhibitory Neuromodulation to Reduce Cigarette Craving and Alter Brain Function in Smokers

Smoking

Enrolled (actual)
40
Serious AEs
Results posted
Jul 2022
Primary outcome: Primary: Changes in Cue-induced Cigarette Craving (Post-treatment - Pre-treatment) as Assessed by TCQ

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Repetitive transcranial magnetic stimulation, MagStim Rapid2 (Device); Sham repetitive transcranial magnetic stimulation (Device)
Age
Adult · 18+ yrs
Sex
All
Sponsor
University of Colorado, Denver
Primary completion
Sep 2019

Outcome Measures

OutcomeResultp-value
PRIMARY
Changes in Cue-induced Cigarette Craving (Post-treatment - Pre-treatment) as Assessed by TCQ
PRIMARY
Changes in Craving Cue-induced fMRI Activity (Post-treatment - Pre-treatment) at Whole Brain Level Using Statistical Parametric Mapping
PRIMARY
Changes in fMRI Connectivity (Post-treatment - Pre-treatment) at Whole Brain Level Using Statistical Parametric Mapping

Summary

The goal of this study is to determine if a specific experimental brain stimulation technique can be used as a non-invasive way to reduce cigarette cravings in current smokers. This study plans to learn more about the way an experimental technique called "transcranial magnetic stimulation" (TMS) affects a specific part of the brain, called the insula. Some research suggests that this part of the brain plays an important role in craving. The investigators plan to study the effects of TMS using standard surveys and magnetic resonance imaging (MRI) of subjects' brain. For interested participants, this study requires a single 3 hour appointment, which will include MRI of the brain as well as TMS.

Eligibility Criteria

Inclusion Criteria

  • Age 18-55
  • Ability to provide informed consent
  • Self-reported current average daily cigarette consumption >10/day for at least 1 year
  • Self-reported motivation to quit smoking

Exclusion Criteria

  • MRI/TMS exclusions, including
  • Claustrophobia
  • Intracranial or spinal hardware
  • Pacemakers
  • MR-incompatible devices (Examples: pacemaker, deep brain stimulator, vagal nerve stimulator, cochlear implant, insulin pump, implanted medication pump, bone stimulator, implanted defibrillator)
  • History of metal objects or fragments in the eye or skull, including shrapnel or metal plates
  • History of stroke or other brain lesion
  • History of attempted suicide or suicidal ideation
  • Personal history of headaches, seizures, epilepsy, or status epilepticus
  • Family history of epilepsy
  • Medications known to lower seizure threshold (e.g., tricyclic antidepressants, antipsychotics, psychostimulants)
  • Increased intracranial pressure, hydrocephalus, or pseudotumor cerebri
  • Unstable coronary artery disease
  • Current pregnancy or positive urine pregnancy test
  • Neurological illness
  • Prior neurosurgery
  • Schizophrenia
  • Bipolar disorder
  • Current (within the last two months) major depressive disorder
  • Substance dependence or positive urinalysis for opiates, stimulants, cannabis, or sedative on the day of testing
  • Alcohol dependence or positive breath test for alcohol on the day of testing
  • Use of tobacco products other than cigarettes.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02590640). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search